1. Home
  2. DH vs EOLS Comparison

DH vs EOLS Comparison

Compare DH & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Definitive Healthcare Corp.

DH

Definitive Healthcare Corp.

HOLD

Current Price

$1.54

Market Cap

283.1M

Sector

Technology

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$4.28

Market Cap

304.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DH
EOLS
Founded
2011
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
283.1M
304.0M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
DH
EOLS
Price
$1.54
$4.28
Analyst Decision
Hold
Strong Buy
Analyst Count
4
6
Target Price
$4.04
$17.40
AVG Volume (30 Days)
321.9K
1.3M
Earning Date
02-26-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$242,275,000.00
$285,823,000.00
Revenue This Year
N/A
$13.70
Revenue Next Year
N/A
$13.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.10
52 Week Low
$1.68
$4.09
52 Week High
$5.68
$17.12

Technical Indicators

Market Signals
Indicator
DH
EOLS
Relative Strength Index (RSI) 18.90 31.90
Support Level $2.21 $4.09
Resistance Level $2.58 $4.61
Average True Range (ATR) 0.13 0.27
MACD -0.07 0.02
Stochastic Oscillator 0.52 22.11

Price Performance

Historical Comparison
DH
EOLS

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: